Literature DB >> 31727345

Possible role of peptide YY (PYY) in the pathophysiology of irritable bowel syndrome (IBS).

Magdy El-Salhy1, Jan Gunnar Hatlebakk2, Trygve Hausken3.   

Abstract

Irritable bowel syndrome (IBS) is a common gastrointestinal disorder of unknown aetiology for which there is no effective treatment. Although IBS does not increase mortality, it reduces the quality of life and is an economic burden to both the patients themselves and society as a whole. Peptide YY (PYY) is localized in endocrine cells located in the ileum, colon and rectum. The concentration of PYY and the density of PYY cells are decreased in both the colon and rectum but unchanged in the ileum of patients with IBS. The low density of PYY cells in the large intestine may be caused by a decreased number of stem cells and their progeny toward endocrine cells. PYY regulates the intestinal motility, secretion and absorption as well as visceral sensitivity via modulating serotonin release. An abnormality in PYY may therefore contribute to the intestinal dysmotility and visceral hypersensitivity seen in IBS patients. Diet management involving consuming a low-FODMAP diet restores the density of PYY cells in the large intestine and improves abdominal symptoms in patients with IBS. This review shows that diet management appears to be a valuable tool for correcting the PYY abnormalities in the large intestine of IBS patients in the clinic.
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  IBS; Motility; NPY; Secretion, stem cells; Visceral hypersensitivity

Year:  2019        PMID: 31727345     DOI: 10.1016/j.npep.2019.101973

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  8 in total

1.  Peptide YY 3-36 attenuates trinitrobenzene sulfonic acid-induced colitis in mice by modulating Th1/Th2 differentiation.

Authors:  Zhiqiang Li; Xiaoyuan Kuang; Tao Chen; Tao Shen; Jiahong Wu
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

2.  Density of Musashi‑1‑positive stem cells in the stomach of patients with irritable bowel syndrome.

Authors:  Magdy El-Salhy; Trygve Hausken; Jan Gunnar Hatlebakk
Journal:  Mol Med Rep       Date:  2020-08-04       Impact factor: 2.952

3.  Chronic Metformin Therapy is Associated with a Lower Risk of Hemorrhoid in Patients with Type 2 Diabetes Mellitus.

Authors:  Chin-Hsiao Tseng
Journal:  Front Pharmacol       Date:  2021-02-16       Impact factor: 5.810

4.  Altered Brain Functional Asymmetry in Patients With Major Depressive Disorder Related to Gastrointestinal Symptoms.

Authors:  Xiaoya Fu; Yudan Ding; Jindong Chen; Feng Liu; Huabing Li; Jingping Zhao; Wenbin Guo
Journal:  Front Neurosci       Date:  2022-02-17       Impact factor: 4.677

5.  Fecal microbiota transplantation for irritable bowel syndrome: An intervention for the 21st century.

Authors:  Magdy El-Salhy; Tanisa Patcharatrakul; Sutep Gonlachanvit
Journal:  World J Gastroenterol       Date:  2021-06-14       Impact factor: 5.742

6.  Serotonin involvement in okadaic acid-induced diarrhoea in vivo.

Authors:  M Carmen Louzao; Celia Costas; Paula Abal; Toshiyuki Suzuki; Ryuichi Watanabe; Natalia Vilariño; Cristina Carrera; Andrea Boente-Juncal; Carmen Vale; Mercedes R Vieytes; Luis M Botana
Journal:  Arch Toxicol       Date:  2021-06-20       Impact factor: 5.153

Review 7.  Molecular Mechanisms of Microbiota-Mediated Pathology in Irritable Bowel Syndrome.

Authors:  Yoshiyuki Mishima; Shunji Ishihara
Journal:  Int J Mol Sci       Date:  2020-11-17       Impact factor: 5.923

Review 8.  The trace aminergic system: a gender-sensitive therapeutic target for IBS?

Authors:  Lesha Pretorius; Carine Smith
Journal:  J Biomed Sci       Date:  2020-09-28       Impact factor: 8.410

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.